<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2024000100007</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2024000100007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio observacional retrospectivo de eventos adversos asociados al tratamiento de COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Retrospective observational study of adverse events associated with the treatments used for COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Buendía-Bravo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Serna-Romero]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Cruz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario del Sureste Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Arganda del Rey Madrid]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>35</fpage>
<lpage>39</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2024000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivos: Cuantificar y clasificar los eventos adversos (EA) asociados a los tratamientos empleados para la COVID-19. Describir los medicamentos empleados y su frecuencia de utilización.  Material y métodos: Estudio retrospectivo, unicéntrico, que incluye pacientes adultos con infección confirmada por SARS-CoV-2 con fecha de ingreso hospitalario entre el 13/03/2020 y 13/04/2020 y con fecha de alta o exitus anterior a 31/05/2020. El período de estudio fue el ingreso y los 30 días posteriores al alta. Se registraron datos demográficos, clínicos, relativos al tratamiento y a los EA. Se categorizó la probabilidad de causalidad del fármaco mediante el algoritmo de Karch y Lasagna modificado.  Resultados: Se incluyeron 183 pacientes de los cuales en el 51% se registró algún evento adverso. Se utilizaron hasta 9 fármacos diferentes. La combinación más utilizada fue hidroxicloroquina más azitromicina (57,5%). Se notificaron 142 EA durante el ingreso, siendo los más prevalentes los trastornos hematológicos (24,6%) y gastrointestinales (15,5%). Un 29,6% son producidos probable o posiblemente por fármacos usados para el tratamiento de la COVID-19. El medicamento que produjo más reacciones adversas fue el lopinavir-ritonavir (25% de pacientes). Se detectaron 7 interacciones farmacológicas que produjeron alargamiento del intervalo QT del electrocardiograma. En el período de estudio, la prevalencia de tromboembolismo es del 13,1%.  Conclusiones: Casi un tercio de los eventos adversos registrados durante la primera fase de la pandemia, pudieron ser debidos a los tratamientos empleados. La profilaxis anticoagulante adecuada y evitar las interacciones, son las principales claves para evitar problemas relacionados con medicamentos en los pacientes con COVID-19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objectives: Quantify and classify adverse events (AE) associated with the treatments used for COVID-19. Describe the medication used and its frequency of use.  Material and methods: A retrospective, single-center study, including adult patients with confirmed SARS-CoV-2 infection, hospital admission date between March 13th, 2020 and April 13th, 2020 and with a discharge or death date prior to May 31st, 2020. The study period was from the admission date and until 30 days after discharge. Demographic data, clinical data, treatment and adverse events were recorded. The probability of drug causality was categorized using the modified Karch and Lasagna algorithm.  Results: 183 patients were included of which 51% had some adverse event. Up to 9 different drugs were used. The most used combination was hydroxychloroquine plus azithromycin (57.5%). 142 AE were reported during admission, being haematological (24.6%) and gastrointestinal (15.5%) disorders the most prevalent. 29.6% are probably or possibly produced by drugs used for the treatment of COVID-19. The drug that caused the most adverse reactions was lopinavirritonavir (25% of patients). Seven drug interactions were detected that produced lengthening of the QT interval of the electrocardiogram. In the study period, the prevalence of thromboembolism is 13.1%.  Conclusions: Almost a third of the adverse events registered during the first phase of the pandemic could be due to the treatment used. Adequate anticoagulant prophylaxis and avoiding interactions are the main keys to prevent drug-related problems in patients with COVID-19.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="es"><![CDATA[interacción]]></kwd>
<kwd lng="en"><![CDATA[COVID]]></kwd>
<kwd lng="en"><![CDATA[security]]></kwd>
<kwd lng="en"><![CDATA[interaction]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Guidance for managing ethical issues in infectious disease outbreak]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Tratamientos disponibles sujetos a condiciones especiales de acceso para el manejo de la infección respiratoria por SARS-CoV-2]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug events and medication errors: detection and classification method]]></article-title>
<source><![CDATA[Quality and Safety in Health Care]]></source>
<year>2004</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>306-14</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero-López]]></surname>
<given-names><![CDATA[M.J]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Hernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maderuelo-Fernández]]></surname>
<given-names><![CDATA[J.A]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido-Corro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Gil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acontecimientos adversos prevenibles causados por medicamentos en pacientes hospitalizados]]></article-title>
<source><![CDATA[Medicina Clínica]]></source>
<year>2006</year>
<volume>126</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>81-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero López]]></surname>
<given-names><![CDATA[M.J]]></given-names>
</name>
<name>
<surname><![CDATA[Codina Jané]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tamés Alonso]]></surname>
<given-names><![CDATA[M.J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Encinas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<collab>Grupo de trabajo Ruiz-Jarabo 2000</collab>
<article-title xml:lang=""><![CDATA[Errores de medicación: estandarización de la terminología y clasificación]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2003</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>137-49</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo]]></surname>
<given-names><![CDATA[C.A]]></given-names>
</name>
<name>
<surname><![CDATA[Busto]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Sellers]]></surname>
<given-names><![CDATA[E.M]]></given-names>
</name>
<name>
<surname><![CDATA[Sandor]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[E.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A method for estimating the probability of adverse drug reactions]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>1981</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>239-45</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19. Informe: 9]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colorio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sociedad Argentina de Hematología. Trombocitopenia inducida por heparina (TIH)]]></article-title>
<source><![CDATA[Hematología]]></source>
<year>2012</year>
<volume>16</volume>
<page-range>25-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<collab>Centro de Coordinación de Alertas y Emergencias sanitarias</collab>
<collab>Dirección General de Salud Pública, Calidad e Innovación</collab>
<collab>Ministerio de Sanidad</collab>
<source><![CDATA[Manejo clínico del COVID-19: atención hospitalaria]]></source>
<year>2020</year>
<publisher-name><![CDATA[Dirección General de Salud Pública, Calidad e Innovación. Ministerio de Sanidad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casas-Rojo]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Antón-Santos]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Millán-Núñez-Cortés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lumbreras-Bermejo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Rincón]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
<name>
<surname><![CDATA[Roy-Vallejo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19]]></article-title>
<source><![CDATA[Revista Clínica Española]]></source>
<year>2020</year>
<volume>220</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>480-94</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amézaga Menéndez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal Cortés]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Escapa]]></surname>
<given-names><![CDATA[M.G]]></given-names>
</name>
<name>
<surname><![CDATA[Suberviola]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano Lázaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)]]></article-title>
<source><![CDATA[Med Intensiva]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<collab>COVID-19 Treatment Guidelines Panel</collab>
<source><![CDATA[Coronavirus Disease 2019 (COVID19) Treatment Guidelines]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Estados Unidos de America ]]></publisher-loc>
<publisher-name><![CDATA[National Institutes of Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sterne]]></surname>
<given-names><![CDATA[J.A.C]]></given-names>
</name>
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[J.V]]></given-names>
</name>
<name>
<surname><![CDATA[Slutsky]]></surname>
<given-names><![CDATA[A.S]]></given-names>
</name>
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<collab>The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group</collab>
<article-title xml:lang=""><![CDATA[Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>324</volume>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcalde González]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdaba García]]></surname>
<given-names><![CDATA[R.M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis del síndrome de QT largo y su relevancia para la práctica clínica enfermera]]></article-title>
<source><![CDATA[Enferm Cardiol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>76</numero>
<issue>76</issue>
<page-range>27-38</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Nota de Seguridad MUH (FV) 07/2020. Cloroquina/hidroxicloroquina: precauciones y vigilancia de posibles reacciones adversas en pacientes con COVID-19]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercuro]]></surname>
<given-names><![CDATA[N.J]]></given-names>
</name>
<name>
<surname><![CDATA[Yen]]></surname>
<given-names><![CDATA[C.F]]></given-names>
</name>
<name>
<surname><![CDATA[Shim]]></surname>
<given-names><![CDATA[D.J]]></given-names>
</name>
<name>
<surname><![CDATA[Maher]]></surname>
<given-names><![CDATA[T.R]]></given-names>
</name>
<name>
<surname><![CDATA[McCoy]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
<name>
<surname><![CDATA[Zimetbaum]]></surname>
<given-names><![CDATA[P.J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2020</year>
<volume>5</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1036-41</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Arroyo]]></surname>
<given-names><![CDATA[M.J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad en el paciente: prescripción de fármacos que prolongan el intervalo QT]]></article-title>
<source><![CDATA[Farmacia Hospitalaria]]></source>
<year>2015</year>
<numero>5</numero>
<issue>5</issue>
<page-range>227-39</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Nota de Seguridad AEMPS 18/2020. Información acerca del uso de hidroxicloroquina para el tratamiento de COVID-19]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Minno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrosino]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calcaterra]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Di Minno]]></surname>
<given-names><![CDATA[M.N.D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>2020</year>
<volume>46</volume>
<numero>07</numero>
<issue>07</issue>
<page-range>763-71</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="">
<collab>Sociedad Española de Trombosis y Hemostasia</collab>
<source><![CDATA[Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
